Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This study is single-arm, none randomized, open label, two-dose-cohorts, single center
clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients
with BCC. Patients will receive Oshadi D and Oshadi R for 60 -90 days until the planned
surgical excision of the lesion.